BeiGene Announces Closing of Its Initial Public Offering
08 févr. 2016 16h30 HE
|
BeiGene Ltd.
BEIJING, Feb. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (“BeiGene” or “the Company”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological...
BeiGene Announces Pricing of Its Initial Public Offering
02 févr. 2016 21h30 HE
|
BeiGene Ltd.
BEIJING, Feb. 2, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. ("BeiGene" or "the Company"), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs...
U.S. IND Becomes Active for BGB-A317, an Anti-PD-1 Monoclonal Antibody
08 janv. 2016 13h06 HE
|
BeiGene Ltd.
BEIJING, Jan. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of...
BeiGene Presents Clinical Data for BTK Inhibitor BGB-3111 at 57th ASH Annual Meeting
07 déc. 2015 18h00 HE
|
BeiGene Ltd.
BEIJING, Dec. 7, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Receives 2015 R&D Achievement of Year at BayHelix China Pharmaceutical Awards
17 nov. 2015 08h00 HE
|
BeiGene Ltd.
BEIJING, Nov. 17, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Appoints Dr. Zhengming Du as Senior Vice President, Head of Chemistry and Manufacturing Controls
09 nov. 2015 08h00 HE
|
BeiGene Ltd.
BEIJING, Nov. 9, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Announces Appointment of Dr. RuiRong Yuan as Chief Medical Officer and President of Global Clinical Development
02 nov. 2015 08h00 HE
|
BeiGene Ltd.
BEIJING, Nov. 2, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Announces Abstracts to be Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
28 oct. 2015 12h11 HE
|
BeiGene Ltd.
BEIJING, Oct. 28, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Doses First Patient in China With BGB-283 for Solid Tumors
12 oct. 2015 10h47 HE
|
BeiGene Ltd.
BEIJING, Oct. 12, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...
BeiGene Appoints Changzhen Wu as Head of Manufacturing Operations
30 sept. 2015 08h00 HE
|
BeiGene Ltd.
BEIJING, Sept. 30, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer,...